Written by students who passed Immediately available after payment Read online or as PDF Wrong document? Swap it for free 4.6 TrustPilot
logo-home
Document preview thumbnail
Preview 4 out of 69 pages
Exam (elaborations)

WGU D345 Objective Assessment (Latest 2026 Update) Psychopharmacology for Advanced Psychiatric Mental Health Practice Guide| 100% Verified Questions & Answers | Grade A

Document preview thumbnail
Preview 4 out of 69 pages

WGU D345 Objective Assessment (Latest 2026 Update) Psychopharmacology for Advanced Psychiatric Mental Health Practice Guide| 100% Verified Questions & Answers | Grade A QUESTION Steps of Activation for G-Proteins Answer: 1. Neurotransmitter binds GPCR → conformational change. 2. G-protein activated: GDP on α is swapped for GTP. 3. α-subunit (with GTP) + βγ complex separate → both can affect target proteins. 4. Effector activated: o Adenylate cyclase → ↑ or ↓ cAMP. o Phospholipase C → produces IP₃ + DAG → ↑ intracellular Ca²⁺. o Ion channels may open/close indirectly. 5. Signal amplification: one NT binding → many second messengers. 6. Termination: GTP hydrolyzed back to GDP → system resets. QUESTION Clinical Significance of G-Proteins Answer: · Many psychiatric and cardiovascular drugs act on GPCRs (antidepressants, antipsychotics, beta-blockers). · Dysregulation contributes to schizophrenia, depression, anxiety, and addiction. QUESTION Pharmacokinetics (PK) Answer: PK = ADME → Absorb, Distribute, Metabolize, Excrete. Definition What the body does to the drug Absorption - How the drug enters the bloodstream.Affected by: route (oral, IV, IM, subcutaneous), pH, gastric emptying, intestinal motility, first-pass metabolism. Distribution - How drug moves into tissues.Affected by: blood flow, protein binding (albumin), lipid solubility, tissue permeability, body fat. Metabolism (Biotransformation) - How the body breaks down the drug.Affected by: liver enzymes (CYP450), age, genetics, liver disease, enzyme inducers/inhibitors. Excretion - How the drug leaves the body.Affected by: kidney function (GFR, tubular secretion), urine pH, bile/fecal elimination, half-life. QUESTION Pharmacodynamics (PD) Answer: PD = RDE → Receptors, Dose-response, Effect What the drug does to the body Mechanism of action, receptor binding, dose-response Mechanism of Action → How the drug interacts with receptors (agonist, antagonist, partial agonist). Dose-Response Relationship → Efficacy (max effect) vs Potency (dose required for effect). Therapeutic Window → Balance between desired effect and toxicity. Factors affecting PD:Receptor number & sensitivity (upregulation/downregulation).Patient age (infants & elderly respond differently).Tolerance (chronic use reduces effect).Drug interactions (synergism, antagonism).Genetic variations in receptors (pharmacogenomics).Pathological state (e.g., receptor desensitization in depression, altered neurotransmission in schizophrenia). QUESTION Factors affecting PK and PD Answer: Age: neonates (immature metabolism/excretion), elderly (reduced clearance, altered receptor sensitivity). Body composition: fat vs muscle affects distribution. Gender & hormones: can alter metabolism and receptor sensitivity. Genetics: affects CYP450 metabolism (PK) & receptor response (PD). Comorbidities: liver/kidney disease alter PK; neurologic/cardiovascular disease may alter PD. Drug interactions: enzyme induction/inhibition (PK) and synergism/antagonism at receptors (PD). Tolerance & dependence: PK tolerance (increased metabolism) or PD tolerance (receptor downregulation). QUESTION Agonist Answer: A drug that binds to a receptor and activates it fully Mimics the natural ligand → produces full biological response Example: Morphine at μ-opioid receptors (pain relief, euphoria) QUESTION Antagonist Answer: A drug that binds to a receptor but does not activate it Blocks the natural ligand or agonist from binding → no activation Example: Naloxone (blocks opioids at μ-opioid receptor) QUESTION Partial Agonist Answer: Binds to receptor and partially activates it, even at full dose Lower efficacy than a full agonist; can act as antagonist in presence of full agonist Example: Buprenorphine (partial μ-opioid agonist: analgesia with ceiling effect, less risk of respiratory depression) QUESTION Inverse Agonist Answer: Binds to receptor and produces the opposite effect of an agonist Stabilizes receptor in its inactive state, reducing baseline activity Example: Some antihistamines (e.g., loratadine at H1 receptor) are inverse agonists rather than "pure antagonists" QUESTION Depolarization Answer: Cell membrane potential becomes less negative (moves toward +) → neuron "fires" Sodium (Na⁺) channels open → Na⁺ rushes into cell Basis of action potential initiation (e.g., when threshold is reached at axon hillock) QUESTION Repolarization Answer: Return of membrane potential toward resting state (~ -70mV) Potassium (K⁺) channels open → K⁺ flows out of cell Essential for resetting neuron to fire again QUESTION (Hyperpolarization) Answer: (bonus term) Membrane becomes more negative than resting potential Continued K⁺ efflux or Cl⁻ influx Makes neuron less likely to fire (inhibition) QUESTION Neuron Action Potential Terms Mnemonic Answer: Agonist = Go (activates receptor). Antagonist = Against (blocks receptor). Partial Agonist = Part-time (some activation, weaker effect). Inverse Agonist = Inverse (opposite effect, pushes receptor below baseline). Depolarization = Na⁺ In ("influx excites

Content preview

WGUl D345l Objectivel Assessmentl (Latestl
2026l Update)l Psychopharmacologyl forl
Advancedl Psychiatricl Mentall Healthl
Practicel Guide|l 100%l Verifiedl Questionsl
&l Answersl |l Gradel A

Q:l Stepsl ofl Activationl forl G-Proteins
Answer:
1.l Neurotransmitterl bindsl GPCRl →l conformationall change.
2.l G-proteinl activated:l GDPl onl αl isl swappedl forl GTP.
3.l α-subunitl (withl GTP)l +l βγl complexl separatel →l bothl canl affectl targetl proteins.
4.l Effectorl activated:
ol Adenylatel cyclasel →l ↑l orl ↓l cAMP.
ol Phospholipasel Cl →l producesl IP₃l +l DAGl →l ↑l intracellularl Ca²⁺.
ol Ionl channelsl mayl open/closel indirectly.
5.l Signall amplification:l onel NTl bindingl →l manyl secondl messengers.
6.l Termination:l GTPl hydrolyzedl backl tol GDPl →l systeml resets.



Q:l Clinicall Significancel ofl G-Proteins
Answer:
·l Manyl psychiatricl andl cardiovascularl drugsl actl onl GPCRsl (antidepressants,l
antipsychotics,l beta-blockers).
·l Dysregulationl contributesl tol schizophrenia,l depression,l anxiety,l andl addiction.



Q:l Pharmacokineticsl (PK)
Answer:
PKl =l ADMEl →l Absorb,l Distribute,l Metabolize,l Excrete.

,Definition
Whatl thel bodyl doesl tol thel drug

Absorptionl -l Howl thel drugl entersl thel bloodstream.Affectedl by:l routel (oral,l IV,l IM,l
subcutaneous),l pH,l gastricl emptying,l intestinall motility,l first-passl metabolism.

Distributionl -l Howl drugl movesl intol tissues.Affectedl by:l bloodl flow,l proteinl bindingl
(albumin),l lipidl solubility,l tissuel permeability,l bodyl fat.

Metabolisml (Biotransformation)l -l Howl thel bodyl breaksl downl thel drug.Affectedl by:l
liverl enzymesl (CYP450),l age,l genetics,l liverl disease,l enzymel inducers/inhibitors.

Excretionl -l Howl thel drugl leavesl thel body.Affectedl by:l kidneyl functionl (GFR,l tubularl
secretion),l urinel pH,l bile/fecall elimination,l half-life.



Q:l Pharmacodynamicsl (PD)
Answer:
PDl =l RDEl →l Receptors,l Dose-response,l Effect

Whatl thel drugl doesl tol thel body
Mechanisml ofl action,l receptorl binding,l dose-response

Mechanisml ofl Actionl →l Howl thel drugl interactsl withl receptorsl (agonist,l antagonist,l
partiall agonist).

Dose-Responsel Relationshipl →l Efficacyl (maxl effect)l vsl Potencyl (dosel requiredl forl
effect).

Therapeuticl Windowl →l Balancel betweenl desiredl effectl andl toxicity.

Factorsl affectingl PD:Receptorl numberl &l sensitivityl (upregulation/downregulation).Patientl
agel (infantsl &l elderlyl respondl differently).Tolerancel (chronicl usel reducesl effect).Drugl
interactionsl (synergism,l antagonism).Geneticl variationsl inl receptorsl
(pharmacogenomics).Pathologicall statel (e.g.,l receptorl desensitizationl inl depression,l alteredl
neurotransmissionl inl schizophrenia).

,Q:l Factorsl affectingl PKl andl PD
Answer:
Age:l neonatesl (immaturel metabolism/excretion),l elderlyl (reducedl clearance,l alteredl
receptorl sensitivity).

Bodyl composition:l fatl vsl musclel affectsl distribution.

Genderl &l hormones:l canl alterl metabolisml andl receptorl sensitivity.

Genetics:l affectsl CYP450l metabolisml (PK)l &l receptorl responsel (PD).

Comorbidities:l liver/kidneyl diseasel alterl PK;l neurologic/cardiovascularl diseasel mayl alterl
PD.

Drugl interactions:l enzymel induction/inhibitionl (PK)l andl synergism/antagonisml atl
receptorsl (PD).

Tolerancel &l dependence:l PKl tolerancel (increasedl metabolism)l orl PDl tolerancel (receptorl
downregulation).



Q:l Agonist
Answer:
Al drugl thatl bindsl tol al receptorl andl activatesl itl fully

Mimicsl thel naturall ligandl →l producesl fulll biologicall response

Example:l Morphinel atl μ-opioidl receptorsl (painl relief,l euphoria)



Q:l Antagonist
Answer:
Al drugl thatl bindsl tol al receptorl butl doesl notl activatel it

Blocksl thel naturall ligandl orl agonistl froml bindingl →l nol activation

, Example:l Naloxonel (blocksl opioidsl atl μ-opioidl receptor)



Q:l Partiall Agonist
Answer:
Bindsl tol receptorl andl partiallyl activatesl it,l evenl atl fulll dose

Lowerl efficacyl thanl al fulll agonist;l canl actl asl antagonistl inl presencel ofl fulll agonist

Example:l Buprenorphinel (partiall μ-opioidl agonist:l analgesial withl ceilingl effect,l lessl riskl
ofl respiratoryl depression)



Q:l Inversel Agonist
Answer:
Bindsl tol receptorl andl producesl thel oppositel effectl ofl anl agonist

Stabilizesl receptorl inl itsl inactivel state,l reducingl baselinel activity

Example:l Somel antihistaminesl (e.g.,l loratadinel atl H1l receptor)l arel inversel agonistsl
ratherl thanl "purel antagonists"



Q:l Depolarization
Answer:
Celll membranel potentiall becomesl lessl negativel (movesl towardl +)l →l neuronl "fires"

Sodiuml (Na⁺)l channelsl openl →l Na⁺l rushesl intol cell

Basisl ofl actionl potentiall initiationl (e.g.,l whenl thresholdl isl reachedl atl axonl hillock)



Q:l Repolarization
Answer:

Document information

Uploaded on
March 23, 2026
Number of pages
69
Written in
2025/2026
Type
Exam (elaborations)
Contains
Questions & answers
CA$17.07

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Seller avatar
Reputation scores are based on the amount of documents a seller has sold for a fee and the reviews they have received for those documents. There are three levels: Bronze, Silver and Gold. The better the reputation, the more your can rely on the quality of the sellers work.
nurse_steph
3.9
(1751)
Sold
9850
Followers
5153
Items
8185
Last sold
23 hours ago



Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their tests and reviewed by others who've used these notes.

Didn't get what you expected? Choose another document

No worries! You can instantly pick a different document that better fits what you're looking for.

Pay as you like, start learning right away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and aced it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions